{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:10Z","timestamp":1792784890453,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianjin Key Medical Discipline Construction Projec"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373365"],"award-info":[{"award-number":["82373365"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Special Project for Collaborative Innovation in Beijing-Tianjin-Hebei"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-68108-2","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:15:04Z","timestamp":1767831304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Lu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4281-5840","authenticated-orcid":false,"given":"Shujie","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huikai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2625-2006","authenticated-orcid":false,"given":"Yongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-1730","authenticated-orcid":false,"given":"Jihui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5979-5213","authenticated-orcid":false,"given":"Tianqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"68108_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"68108_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/01.sla.0000197706.21803.a1","volume":"243","author":"N Portolani","year":"2006","unstructured":"Portolani, N. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann. Surg. 243, 229\u2013235 (2006).","journal-title":"Ann. Surg."},{"key":"68108_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/SLA.0000000000000710","volume":"261","author":"P Tabrizian","year":"2015","unstructured":"Tabrizian, P., Jibara, G., Shrager, B., Schwartz, M. & Roayaie, S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann. Surg. 261, 947\u2013955 (2015).","journal-title":"Ann. Surg."},{"key":"68108_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","volume":"38","author":"H Imamura","year":"2003","unstructured":"Imamura, H. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol. 38, 200\u2013207 (2003).","journal-title":"J. Hepatol."},{"key":"68108_CR5","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1097\/JS9.0000000000001467","volume":"110","author":"L Liu","year":"2024","unstructured":"Liu, L. Development and comprehensive validation of a predictive prognosis model for very early HCC recurrence within one year after curative resection: a multicenter cohort study. Int. J. Surg. 110, 3401\u20133411 (2024).","journal-title":"Int. J. Surg."},{"key":"68108_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3748\/wjg.v12.i1.99","volume":"12","author":"BW Kim","year":"2006","unstructured":"Kim, B. W., Kim, Y. B., Wang, H. J. & Kim, M. W. Risk factors for immediate post-operative fatal recurrence after curative resection of hepatocellular carcinoma. World J. Gastroenterol. 12, 99\u2013104 (2006).","journal-title":"World J. Gastroenterol."},{"key":"68108_CR7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s12072-022-10422-8","volume":"16","author":"CW Lee","year":"2022","unstructured":"Lee, C. W. A proposal for T1 subclassification in hepatocellular carcinoma: reappraisal of the AJCC. Hepatol. Int. 16, 1353\u20131367 (2022).","journal-title":"Hepatol. Int."},{"key":"68108_CR8","doi-asserted-by":"publisher","first-page":"8436","DOI":"10.1245\/s10434-022-12495-z","volume":"29","author":"T Orimo","year":"2022","unstructured":"Orimo, T. Hepatectomy is beneficial in select patients with multiple hepatocellular carcinomas. Ann. Surg. Oncol. 29, 8436\u20138445 (2022).","journal-title":"Ann. Surg. Oncol."},{"key":"68108_CR9","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa, G. K. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1, EVIDoa2100070 (2022).","journal-title":"NEJM Evid."},{"key":"68108_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"68108_CR11","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin, S. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 402, 1835\u20131847 (2023).","journal-title":"Lancet"},{"key":"68108_CR12","doi-asserted-by":"crossref","unstructured":"Yopp, A. LBA39 Updated efficacy and safety data from IMbrave050: phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC). Annals of Oncology. 35, S1230 (2024).","DOI":"10.1016\/j.annonc.2024.08.2279"},{"key":"68108_CR13","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41591-023-02786-7","volume":"30","author":"K Wang","year":"2024","unstructured":"Wang, K. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat. Med. 30, 708\u2013715 (2024).","journal-title":"Nat. Med."},{"key":"68108_CR14","doi-asserted-by":"crossref","unstructured":"Blank, C. U. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N. Engl. J. Med. 391, 1696\u20131708 (2024).","DOI":"10.1056\/NEJMoa2402604"},{"key":"68108_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet\u00a0391, 1163\u20131173 (2018).","journal-title":"Lancet"},{"key":"68108_CR16","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin, S. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol. 9, 1651\u20131659 (2023).","journal-title":"JAMA Oncol."},{"key":"68108_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03356-5","volume":"22","author":"L Xu","year":"2024","unstructured":"Xu, L. Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial. BMC Med. 22, 172 (2024).","journal-title":"BMC Med."},{"key":"68108_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","volume":"21","author":"JM Llovet","year":"2024","unstructured":"Llovet, J. M. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 21, 294\u2013311 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68108_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","volume":"76","author":"B Scheiner","year":"2022","unstructured":"Scheiner, B. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J. Hepatol. 76, 353\u2013363 (2022).","journal-title":"J. Hepatol."},{"key":"68108_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41586-024-08328-6","volume":"637","author":"N Hollmann","year":"2025","unstructured":"Hollmann, N. Accurate predictions on small data with a tabular foundation model. Nature 637, 319\u2013326 (2025).","journal-title":"Nature"},{"key":"68108_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","volume":"7","author":"TU Marron","year":"2022","unstructured":"Marron, T. U. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 219\u2013229 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"68108_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","volume":"7","author":"AO Kaseb","year":"2022","unstructured":"Kaseb, A. O. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 208\u2013218 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"68108_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","volume":"2","author":"WJ Ho","year":"2021","unstructured":"Ho, W. J. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat. Cancer 2, 891\u2013903 (2021).","journal-title":"Nat. Cancer"},{"key":"68108_CR24","doi-asserted-by":"publisher","first-page":"e004656","DOI":"10.1136\/jitc-2022-004656","volume":"10","author":"Y Xia","year":"2022","unstructured":"Xia, Y. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J. Immunother. Cancer 10, e004656 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"68108_CR25","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet, J. M. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1399\u20131410 (2023).","journal-title":"Lancet Oncol."},{"key":"68108_CR26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","volume":"30","author":"H-D Kim","year":"2024","unstructured":"Kim, H.-D. et al. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat. Med. 30, 699\u2013707 (2024).","journal-title":"Nat. Med."},{"key":"68108_CR27","doi-asserted-by":"publisher","first-page":"e001435","DOI":"10.1136\/jitc-2020-001435","volume":"8","author":"K Shigeta","year":"2020","unstructured":"Shigeta, K. et al. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J. Immunother. Cancer 8, e001435 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"68108_CR28","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/hep.31921","volume":"74","author":"C Yi","year":"2021","unstructured":"Yi, C. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology 74, 2544\u20132560 (2021).","journal-title":"Hepatology"},{"key":"68108_CR29","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","volume":"25","author":"A D\u2019Alessio","year":"2024","unstructured":"D\u2019Alessio, A. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 25, 1465\u20131475 (2024).","journal-title":"Lancet Oncol."},{"key":"68108_CR30","first-page":"6","volume":"59","author":"YX Xia","year":"2021","unstructured":"Xia, Y. X. Surgical treatment of primary liver cancer: a report of 10 966 cases. Zhonghua Wai Ke Za Zhi 59, 6\u201317 (2021).","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"68108_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/hep.31327","volume":"73","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology 73, 158\u2013191 (2021).","journal-title":"Hepatology"},{"key":"68108_CR32","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1200\/JCO.2023.41.16_suppl.4023","volume":"41","author":"W Wei","year":"2023","unstructured":"Wei, W. Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A\/B hepatocellular carcinoma patients beyond Milan criteria: a multi-center, phase 3, randomized, controlled clinical trial. J. Clin. Oncol. 41, 4023\u20134023 (2023).","journal-title":"J. Clin. Oncol."},{"key":"68108_CR33","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.18.02184","volume":"37","author":"X Wei","year":"2019","unstructured":"Wei, X. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J. Clin. Oncol. 37, 2141\u20132151 (2019).","journal-title":"J. Clin. Oncol."},{"key":"68108_CR34","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s12072-019-09981-0","volume":"13","author":"C Li","year":"2019","unstructured":"Li, C. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (\u2265 10 cm): a multicenter propensity matching analysis. Hepatol. Int. 13, 736\u2013747 (2019).","journal-title":"Hepatol. Int."},{"key":"68108_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000102901","volume":"24","author":"XP Chen","year":"2007","unstructured":"Chen, X. P. Role of mesohepatectomy with or without transcatheter arterial chemoembolization for large centrally located hepatocellular carcinoma. Dig. Surg. 24, 208\u2013213 (2007).","journal-title":"Dig. Surg."},{"key":"68108_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107106","volume":"49","author":"J Zhao","year":"2023","unstructured":"Zhao, J. Neoadjuvant drug-eluting bead transarterial chemoembolization and tislelizumab therapy for resectable or borderline resectable hepatocellular carcinoma: a propensity score matching analysis. Eur. J. Surg. Oncol. 49, 107106 (2023).","journal-title":"Eur. J. Surg. Oncol."},{"key":"68108_CR37","doi-asserted-by":"publisher","first-page":"0054","DOI":"10.1097\/HC9.0000000000000054","volume":"7","author":"C Guo","year":"2023","unstructured":"Guo, C. Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: a phase II trial. Hepatol. Commun. 7, 0054 (2023).","journal-title":"Hepatol. Commun."},{"key":"68108_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000529574","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo, M. Achievement of complete response and drug-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study. Liver Cancer 12, 321\u2013338 (2023).","journal-title":"Liver Cancer"},{"key":"68108_CR39","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.3390\/ijms23115970","volume":"23","author":"SM Decking","year":"2022","unstructured":"Decking, S. M. LDHB overexpression can partially overcome T cell inhibition by lactic acid. Int. J. Mol. Sci. 23, 5970 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"68108_CR40","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.7150\/ijbs.35094","volume":"15","author":"Y Guo","year":"2019","unstructured":"Guo, Y. Combined aberrant expression of NDRG2 and LDHA predicts hepatocellular carcinoma prognosis and mediates the anti-tumor effect of gemcitabine. Int. J. Biol. Sci. 15, 1771\u20131786 (2019).","journal-title":"Int. J. Biol. Sci."},{"key":"68108_CR41","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.3390\/cells10113065","volume":"10","author":"S Udawant","year":"2021","unstructured":"Udawant, S. PI3K pathway inhibition with NVP-BEZ235 hinders glycolytic metabolism in glioblastoma multiforme cells. Cells 10, 3065 (2021).","journal-title":"Cells"},{"key":"68108_CR42","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41392-022-01097-6","volume":"7","author":"H Zeng","year":"2022","unstructured":"Zeng, H. Suppression of PFKFB3-driven glycolysis restrains endothelial-to-mesenchymal transition and fibrotic response. Signal Transduct. Target Ther. 7, 303 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"68108_CR43","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.3390\/ijms23062988","volume":"23","author":"A Asma","year":"2022","unstructured":"Asma, A. & Marc-Andr\u00e9, S. Melatonin signaling pathways implicated in metabolic processes in human granulosa cells (KGN). Int. J. Mol. Sci. 23, 2988 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"68108_CR44","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.3390\/cancers13236142","volume":"13","author":"F Baker","year":"2021","unstructured":"Baker, F. Metabolic rewiring is essential for AML cell survival to overcome autophagy inhibition by loss of ATG3. Cancers (Basel) 13, 6142 (2021).","journal-title":"Cancers (Basel)"},{"key":"68108_CR45","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1073\/pnas.1918611117","volume":"117","author":"S Ketkar","year":"2020","unstructured":"Ketkar, S. Remethylation of Dnmt3a-\/- hematopoietic cells is associated with partial correction of gene dysregulation and reduced myeloid skewing. Proc. Natl. Acad. Sci. USA 117, 3123\u20133134 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68108_CR46","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.3390\/ijms21197415","volume":"21","author":"H Benabdelkamel","year":"2020","unstructured":"Benabdelkamel, H. Serum-based proteomics profiling in adult patients with cystic fibrosis. Int. J. Mol. Sci. 21, 7415 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"68108_CR47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson, P. J. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J. Clin. Oncol. 33, 550\u2013558 (2015).","journal-title":"J. Clin. Oncol."},{"key":"68108_CR48","doi-asserted-by":"publisher","first-page":"23595","DOI":"10.2196\/23595","volume":"23","author":"H Cos","year":"2021","unstructured":"Cos, H. Predicting outcomes in patients undergoing pancreatectomy using wearable technology and machine learning: prospective cohort study. J. Med. Internet Res. 23, 23595 (2021).","journal-title":"J. Med. Internet Res."},{"key":"68108_CR49","doi-asserted-by":"publisher","first-page":"eaau5631","DOI":"10.1126\/science.aau5631","volume":"363","author":"AF Zahrt","year":"2019","unstructured":"Zahrt, A. F. Prediction of higher-selectivity catalysts by computer-driven workflow and machine learning. Science 363, eaau5631 (2019).","journal-title":"Science"},{"key":"68108_CR50","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s42255-022-00620-x","volume":"4","author":"RK Baboota","year":"2022","unstructured":"Baboota, R. K. BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD\/NASH. Nat. Metab. 4, 1007\u20131021 (2022).","journal-title":"Nat. Metab."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68108-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68108-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68108-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T14:04:05Z","timestamp":1770300245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68108-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68108"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-68108-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1358"}}